

Bupaq 0,3 mg/ml Injektionslösung für Hunde und Katzen

Authorised

- Buprenorphine hydrochloride

Product identification

Medicine name:

Bupaq 0,3 mg/ml Injektionslösung für Hunde und Katzen

Bupaq vet 0,3 mg/ml Injektionsvätska, lösning

Active substance:

Buprenorphine hydrochloride

Target species:

Dog

Cat

Route of administration:

Intramuscular use

Intravenous use

Product details

Active substance and strength:

Buprenorphine hydrochloride

0.32 milligram(s) / 1.00 millilitre(s)

Pharmaceutical form:

Solution for injection

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QN02AE01

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Sweden

Package description:

Clear glass vials type II, coated bromobutyl rubber stopper type I, aluminium cap, packed in a cardboard box. Package size: Cardboard box with 10 vials of 2 ml
Clear glass vials type II, coated bromobutyl rubber stopper type I, aluminium cap, packed in a cardboard box. Package size: Cardboard box with 3 vials of 2 ml
Clear glass vials type II, coated bromobutyl rubber stopper type I, aluminium cap, packed in a cardboard box. Package size: Cardboard box with 4 vials of 2 ml
Clear glass vials type II, coated bromobutyl rubber stopper type I, aluminium cap, packed in a cardboard box. Package size: Cardboard box with 5 vials of 2 ml
Clear glass vials type II, coated bromobutyl rubber stopper type I, aluminium cap, packed in a cardboard box. Package size: Cardboard box with 6 vials of 2 ml

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Generic application (Article 13(1) of Directive No 2001/82/EC)

Marketing authorisation holder:

Vetviva Richter GmbH

Marketing authorisation date:

6/10/2017

Manufacturing sites for batch release:

Vetviva Richter GmbH

Responsible authority:

Swedish Medical Products Agency

Authorisation number:

55391

Date of authorisation status change:

6/10/2017

Reference member state:

Austria

Procedure number:

AT/V/0008/002

Concerned member states:

Bulgaria Denmark Estonia France Germany Greece Hungary Latvia
Lithuania Norway Portugal Romania Slovakia Spain Sweden
United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to
www.adrreports.eu/vet

Documents

Summary of Product Characteristics

English (PDF)

Published on: 6/07/2022

Download

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.

Labelling

This document does not exist in this language (English). You can find it in another language below.